{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:14:40Z","timestamp":1740107680526,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100007610","name":"Vlaamse Instelling voor Technologisch Onderzoek","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100007610","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s10067-020-05008-4","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T05:40:41Z","timestamp":1583991641000},"page":"2593-2601","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of maintenance therapy with methotrexate compared with leflunomide for patients with RA having achieved disease control with both these drugs: results of a predefined sub-analysis of CareRA, a pragmatic RCT"],"prefix":"10.1007","volume":"39","author":[{"given":"Veerle","family":"Stouten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stijn","family":"Michiels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9","family":"Westhovens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diederik","family":"De Cock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Belba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Pazmino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristien","family":"Van der Elst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Joly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Verschueren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,12]]},"reference":[{"issue":"6","key":"5008_CR1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/rheumatology\/39.6.655","volume":"39","author":"P Emery","year":"2000","unstructured":"Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomor B et al (2000) A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 39(6):655\u2013665","journal-title":"Rheumatology (Oxford)"},{"key":"5008_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/OARRR.S9448","volume":"2","author":"PB Jones","year":"2010","unstructured":"Jones PB, White DH (2010) Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis. Open Access Rheumatol 2:53\u201371","journal-title":"Open Access Rheumatol"},{"issue":"11","key":"5008_CR3","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1002\/art.1780381111","volume":"38","author":"V Mladenovic","year":"1995","unstructured":"Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, Popovic M, Dimitrijevic M, Zivkovic M, Campion G (1995) Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 38(11):1595\u20131603","journal-title":"Arthritis Rheum"},{"issue":"7","key":"5008_CR4","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s10067-017-3687-5","volume":"36","author":"M Schultz","year":"2017","unstructured":"Schultz M, Keeling SO, Katz SJ, Maksymowych WP, Eurich DT, Hall JJ (2017) Clinical effectiveness and safety of leflunomide in inflammatory arthritis: a report from the RAPPORT database with supporting patient survey. Clin Rheumatol 36(7):1471\u20131478","journal-title":"Clin Rheumatol"},{"issue":"10","key":"5008_CR5","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1136\/ard.60.10.913","volume":"60","author":"DL Scott","year":"2001","unstructured":"Scott DL, Smolen JS, Kalden JR, van de Putte LB, Larsen A, Kvien TK, Schattenkirchner M, Nash P, Oed C, Loew-Friedrich I, European Leflunomide Study Group (2001) Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 60(10):913\u2013923","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"5008_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U","volume":"43","author":"JT Sharp","year":"2000","unstructured":"Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I (2000) Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 43(3):495\u2013505","journal-title":"Arthritis Rheum"},{"issue":"3","key":"5008_CR7","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/BOR.0b013e328344f2e4","volume":"23","author":"O Singer","year":"2011","unstructured":"Singer O, Gibofsky A (2011) Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011? Curr Opin Rheumatol 23(3):288\u2013292","journal-title":"Curr Opin Rheumatol"},{"issue":"9149","key":"5008_CR8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0140-6736(98)09403-3","volume":"353","author":"JS Smolen","year":"1999","unstructured":"Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A et al (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 353(9149):259\u2013266","journal-title":"Lancet"},{"issue":"21","key":"5008_CR9","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1001\/archinte.159.21.2542","volume":"159","author":"V Strand","year":"1999","unstructured":"Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G et al (1999) Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 159(21):2542\u20132550","journal-title":"Arch Intern Med"},{"issue":"3","key":"5008_CR10","first-page":"337","volume":"21","author":"R Wiacek","year":"2012","unstructured":"Wiacek R, Kolossa K, Jankowski T, Jeka S, Karmowski A, Karmowski M, Gworys B (2012) The efficacy and safety of leflunomide in patients with active rheumatoid arthritis. Adv Clin Exp Med 21(3):337\u2013342","journal-title":"Adv Clin Exp Med"},{"issue":"2","key":"5008_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1590\/S0482-50042011000200004","volume":"51","author":"JA Alves","year":"2011","unstructured":"Alves JA, Fialho SC, Morato EF, Castro GR, Zimmermann AF, Ribeiro GG, Neves FS, Pereira IA (2011) Liver toxicity is rare in rheumatoid arthritis patients using combination therapy with leflunomide and methotrexate. Rev Bras Reumatol 51(2):141\u2013144","journal-title":"Rev Bras Reumatol"},{"issue":"3","key":"5008_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3899\/jrheum.120922","volume":"40","author":"P Bird","year":"2013","unstructured":"Bird P, Griffiths H, Tymms K, Nicholls D, Roberts L, Arnold M, Burnet S, de Jager J, Scott J, Zochling J, Littlejohn G (2013) The SMILE study\u2014safety of methotrexate in combination with leflunomide in rheumatoid arthritis. J Rheumatol 40(3):228\u2013235","journal-title":"J Rheumatol"},{"issue":"6","key":"5008_CR13","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/ard.2009.127225","volume":"69","author":"C Gaujoux-Viala","year":"2010","unstructured":"Gaujoux-Viala C, Smolen JS, Landewe R, Dougados M, Kvien TK, Mola EM et al (2010) Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69(6):1004\u20131009","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"5008_CR14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1177\/1759720X16664324","volume":"8","author":"B Hodkinson","year":"2016","unstructured":"Hodkinson B, Magomero KR, Tikly M (2016) Combination leflunomide and methotrexate in refractory rheumatoid arthritis: a biologic sparing approach. Ther Adv Musculoskelet Dis 8(5):172\u2013179","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"8","key":"5008_CR15","first-page":"1521","volume":"31","author":"J Kremer","year":"2004","unstructured":"Kremer J, Genovese M, Cannon GW, Caldwell J, Cush J, Furst DE, Luggen M, Keystone E, Bathon J, Kavanaugh A, Ruderman E, Coleman P, Curtis D, Kopp E, Kantor S, Weisman M, Waltuck J, Lindsley HB, Markenson J, Crawford B, Fernando I, Simpson K, Strand V (2004) Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. J Rheumatol 31(8):1521\u20131531","journal-title":"J Rheumatol"},{"issue":"9","key":"5008_CR16","doi-asserted-by":"publisher","first-page":"726","DOI":"10.7326\/0003-4819-137-9-200211050-00007","volume":"137","author":"JM Kremer","year":"2002","unstructured":"Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE et al (2002) Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137(9):726\u2013733","journal-title":"Ann Intern Med"},{"issue":"1","key":"5008_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/03009740802360632","volume":"38","author":"SS Lee","year":"2009","unstructured":"Lee SS, Park YW, Park JJ, Kang YM, Nam EJ, Kim SI, Lee JH, Yoo WH, Lee SI (2009) Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis. Scand J Rheumatol 38(1):11\u201314","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"5008_CR18","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1590\/S0482-50042012000600003","volume":"52","author":"J Londono","year":"2012","unstructured":"Londono J, Santos AM, Santos PI, Cubidez MF, Guzman C, Valle-Onate R (2012) Therapeutic efficacy and safety of methotrexate + leflunomide in Colombian patients with active rheumatoid arthritis refractory to conventional treatment. Rev Bras Reumatol 52(6):837\u2013845","journal-title":"Rev Bras Reumatol"},{"issue":"3","key":"5008_CR19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/rheumatology\/keh500","volume":"44","author":"P Maddison","year":"2005","unstructured":"Maddison P, Kiely P, Kirkham B, Lawson T, Moots R, Proudfoot D, Reece R, Scott D, Sword R, Taggart A, Thwaites C, Williams E (2005) Leflunomide in rheumatoid arthritis: recommendations through a process of consensus. Rheumatology (Oxford) 44(3):280\u2013286","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"5008_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10067-011-1842-y","volume":"31","author":"GT Sakellariou","year":"2012","unstructured":"Sakellariou GT, Sayegh FE, Kapetanos GA, Berberidis C (2012) Efficacy of leflunomide addition in relation to prognostic factors for patients with active early rheumatoid arthritis failing to methotrexate in daily practice. Clin Rheumatol 31(1):163\u2013167","journal-title":"Clin Rheumatol"},{"issue":"6","key":"5008_CR21","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76(6):960\u2013977","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"5008_CR22","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1136\/annrheumdis-2016-209212","volume":"76","author":"P Verschueren","year":"2017","unstructured":"Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V et al (2017) Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial. Ann Rheum Dis 76(3):511\u2013520","journal-title":"Ann Rheum Dis"},{"key":"5008_CR23","doi-asserted-by":"crossref","unstructured":"Stouten V, Westhovens R, Pazmino S, De Cock D, Van der Elst K, Joly J, Verschueren P, CareRA study group (2019) Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA. Rheumatology (Oxford) 58(12):2284\u20132294","DOI":"10.1093\/rheumatology\/kez213"},{"issue":"9074","key":"5008_CR24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(97)01300-7","volume":"350","author":"M Boers","year":"1997","unstructured":"Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC et al (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350(9074):309\u2013318","journal-title":"Lancet"},{"issue":"1","key":"5008_CR25","first-page":"261","volume":"27","author":"D van der Heijde","year":"2000","unstructured":"van der Heijde D (2000) How to read radiographs according to the Sharp\/van der Heijde method. J Rheumatol 27(1):261\u2013263","journal-title":"J Rheumatol"},{"issue":"1","key":"5008_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.2517-6161.1977.tb01600.x","volume":"39","author":"APLN Dempster","year":"1977","unstructured":"Dempster APLN, Rubin DB (1977) Maximum likelihood from incomplete data via the EM algorithm. J R Stat Soc Ser B Stat Methodol 39(1):1\u201338","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"issue":"7","key":"5008_CR27","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1093\/rheumatology\/kew030","volume":"55","author":"IM Markusse","year":"2016","unstructured":"Markusse IM, Landewe R, Wolterbeek R, Ho M, Jenkins M, van der Heijde D (2016) Linear extrapolation of missing radiographic change scores in clinical trials does not spuriously overestimate group radiographic changes in rheumatoid arthritis. Rheumatology (Oxford) 55(7):1295\u20131300","journal-title":"Rheumatology (Oxford)"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05008-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-020-05008-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05008-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:46:17Z","timestamp":1722559577000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-020-05008-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,12]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["5008"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05008-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2020,3,12]]},"assertion":[{"value":"28 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The study (EudraCT number: 2008-007225-39) was approved by the leading Ethics Committee of the University Hospitals Leuven after consulting the medical ethics committee of each participating center (ref s51411), and all study participants gave their written informed consent before inclusion.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors commit to making the relevant anonymized patient level data available on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing"}},{"value":"The guarantors affirm that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Transparency declaration"}},{"value":"The pragmatic CareRA protocol was strongly inspired by daily interactions of the investigators with RA patients in daily clinical practice. Patients were not formally involved in setting the research question or the outcome measures, nor were they invited to comment on study design or the interpretation of results of this manuscript. However, results of this research will be disseminated to study participants, all stakeholders, and the general public in collaboration with patient organizations and the Belgian patient partners program (trained patients who educate physicians, medicine students, and other health care professionals in collaboration with a rheumatologist).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient involvement"}}]}}